Golden Biotechnology マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Li Yu Wu

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	2.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Does Golden Biotechnology's (GTSM:4132) Share Price Gain of 86% Match Its Business Performance?

Mar 18

Did Golden Biotechnology's (GTSM:4132) Share Price Deserve to Gain 34%?

Dec 03

CEO（最高経営責任者

Li Yu Wu

no data

在職期間

Li Yu Wu serves as President and Director of Golden Biotechnology Corp. and served as its Co-Chief Executive Officer.

Golden Biotechnology マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Golden Biotechnology Corporation, Annual General Meeting, Jun 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Golden Biotechnology Corporation, Annual General Meeting, Apr 28, 2021

Recent updates

New minor risk - Shareholder dilution

New minor risk - Market cap size

Full year 2023 earnings released: NT$2.54 loss per share (vs NT$1.91 loss in FY 2022)

Golden Biotechnology Corporation, Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol

New minor risk - Share price stability

Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer

Less than half of directors are independent

First half 2022 earnings released: NT$1.46 loss per share (vs NT$1.66 loss in 1H 2021)

Full year 2021 earnings released: NT$3.35 loss per share (vs NT$3.11 loss in FY 2020)

Less than half of directors are independent

Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients

Full year 2020 earnings released: NT$3.11 loss per share (vs NT$2.48 loss in FY 2019)

Does Golden Biotechnology's (GTSM:4132) Share Price Gain of 86% Match Its Business Performance?

GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries

Golden Biotechnology Corporation, Annual General Meeting, Apr 28, 2021

New 90-day high: NT$57.90

New 90-day high: NT$55.40

Did Golden Biotechnology's (GTSM:4132) Share Price Deserve to Gain 34%?

Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia

New 90-day low: NT$41.20

First half earnings released

CEO（最高経営責任者

在職期間

Golden Biotechnology マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Golden Biotechnology Corporation, Annual General Meeting, Jun 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Golden Biotechnology Corporation, Annual General Meeting, Apr 28, 2021

Recent updates

New minor risk - Shareholder dilution

New minor risk - Market cap size

Full year 2023 earnings released: NT$2.54 loss per share (vs NT$1.91 loss in FY 2022)

Golden Biotechnology Corporation, Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol

New minor risk - Share price stability

Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer

Less than half of directors are independent

First half 2022 earnings released: NT$1.46 loss per share (vs NT$1.66 loss in 1H 2021)

Full year 2021 earnings released: NT$3.35 loss per share (vs NT$3.11 loss in FY 2020)

Less than half of directors are independent

Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients

Full year 2020 earnings released: NT$3.11 loss per share (vs NT$2.48 loss in FY 2019)

Does Golden Biotechnology's (GTSM:4132) Share Price Gain of 86% Match Its Business Performance?

GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries

Golden Biotechnology Corporation, Annual General Meeting, Apr 28, 2021

New 90-day high: NT$57.90

New 90-day high: NT$55.40

Did Golden Biotechnology's (GTSM:4132) Share Price Deserve to Gain 34%?

Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia

New 90-day low: NT$41.20

First half earnings released

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04